Read by QxMD icon Read

Her2 negative breast cancer

Gaia Griguolo, Stephane Pouderoux, Maria Vittoria Dieci, William Jacot, Céline Bourgier, Federica Miglietta, Nelly Firmin, Pierfranco Conte, Marie Viala, Valentina Guarneri, Amélie Darlix
BACKGROUND: Breast cancer (BC) is one of the solid tumors most commonly associated with leptomeningeal disease (LMD). LMD carries a devastating prognosis; however, disease presentation and prognostic factors are uncertain. SUBJECTS, MATERIALS, AND METHODS: In order to describe patient characteristics, treatment patterns, and factors associated with survival in a contemporary multicentric cohort, 153 consecutive BC patients diagnosed with LMD at two European institutions (2002-2017) were included...
August 17, 2018: Oncologist
Courtney P Williams, Kelly M Kenzik, Andres Azuero, Grant R Williams, Maria Pisu, Karina I Halilova, Stacey A Ingram, Supriya K Yagnik, Andres Forero, Smita Bhatia, Gabrielle B Rocque
BACKGROUND: National Comprehensive Cancer Network (NCCN) guideline-based treatment is a marker of high-quality care. The impact of guideline discordance on cost and health care utilization is unclear. MATERIALS AND METHODS: This retrospective cohort study of Medicare claims data from 2012 to 2015 included women age ≥65 with stage I-III breast cancer receiving care within the University of Alabama at Birmingham Cancer Community Network. Concordance with NCCN guidelines was assessed for treatment regimens...
August 17, 2018: Oncologist
Dan Le, Karen A Gelmon
Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic HER2-negative breast cancer. Areas Covered Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has been shown in phase I-III clinical trials to have single-agent efficacy in breast cancer patients with gBRCAm. The recent phase III OlympiAD study demonstrated a statistically significant progression free survival benefit compared to the chemotherapy control arm, although an overall survival benefit has not been demonstrated...
August 17, 2018: Expert Review of Clinical Pharmacology
Michael Kenn, Dan Cacsire Castillo-Tong, Christian F Singer, Michael Cibena, Heinz Kölbl, Wolfgang Schreiner
PURPOSE: Therapeutic decisions in breast cancer patients crucially depend on the status of estrogen receptor, progesterone receptor and HER2, obtained by immunohistochemistry (IHC). These are known to be inaccurate sometimes, and we demonstrate how to use gene-expression to increase precision of receptor status. METHODS: We downloaded data from 3241 breast cancer patients out of 36 clinical studies. For each receptor, we modelled the mRNA expression of the receptor gene and a co-gene by logistic regression...
August 16, 2018: Breast Cancer Research and Treatment
Shiteng Suo, Dandan Zhang, Fang Cheng, Mengqiu Cao, Jia Hua, Jinsong Lu, Jianrong Xu
OBJECTIVES: To study the added value of mean and entropy of apparent diffusion coefficient (ADC) values at standard (800 s/mm2 ) and high (1500 s/mm2 ) b-values obtained with diffusion-weighted imaging in identifying histologic phenotypes of invasive ductal breast cancer (IDC) with MR imaging. METHODS: One hundred thirty-four IDC patients underwent diffusion-weighted imaging with b-values of 800 and 1500 s/mm2 , and corresponding ADC800 and ADC1500 maps were generated...
August 16, 2018: European Radiology
Gyula Pekar, Ioanna Kasselaki, Agnes P Lukacs, Csaba Dekany, Dan Hellberg, Tibor Tot
AIMS: Genetic heterogeneity can pose a challenge to identifying eligible cases for targeted therapy in the human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 2+ breast carcinoma group. In this study, we characterized this subset of tumors according to clinicopathological parameters. METHODS AND RESULTS: We assessed 1000 tumor cells per case and recorded the number of HER2 and chromosome enumeration probe 17 (CEP17) copies using gene-protein assay slides...
August 16, 2018: Histopathology
S Martel, M Lambertini, R Simon, C Matte, C Prady
Background: Oncotype dx [odx (Genomic Health, Redwood City, CA, U.S.A.)] is an approved prognostic tool for women with node-negative, hormone receptor-positive, her2-negative breast cancer. Because of cost, optimal use of this test is crucial, especially in a publicly funded health care system. We evaluated adherence with our provincial guidelines for odx requests, the management of patients with an intermediate recurrence score (rs), and the cost impact of odx. Methods: This retrospective study included 201 consecutive patients with an odx request from two university institutions in Quebec between May 2012 and December 2014...
August 2018: Current Oncology
V Lambert-Obry, A Gouault-Laliberté, A Castonguay, G Zanotti, T Tran, M Mates, J Lemieux, P Chabot, C Prady, F Couture, J Lachaine
Background: Advanced breast cancer (abc) represents a substantial burden for patients and caregivers. In the present study, we aimed to estimate quality of life (qol), utility, productivity loss, pain, health care resource utilization, and costs for patients with abc, and qol, utility, and productivity loss for their caregivers. Methods: This multicentre prospective non-interventional study was conducted in Canada. Eligible participants were postmenopausal women with estrogen receptor-positive, her2-negative unresectable abc and their caregivers...
August 2018: Current Oncology
Anand A Dalal, Geneviève Gauthier, Patrick Gagnon-Sanschagrin, Rebecca Burne, Annie Guérin, Polly Niravath, Tania Small
INTRODUCTION: Premenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (aBC) often present with aggressive tumor types that lead to poor prognosis, high rates of recurrence, and mortality. Although clinical guidelines provide evidence-based recommendations for optimal treatment and monitoring, there is a dearth of information regarding treatment and monitoring patterns in clinical practice. In this study, we describe treatment and monitoring patterns among premenopausal women with HR+/HER2- aBC in real-world practice...
August 13, 2018: Advances in Therapy
Roger K C Ngan
Hormone therapy, rather than chemotherapy, is recommended for hormone-receptor positive (HR+), human epidermal receptor 2 negative (HER2-) advanced or metastatic breast cancer (A/MBC) according to the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines, unless in visceral crisis in which chemotherapy is indicated. Hormonal monotherapy of selective estrogen receptor modulator (SERM) or selective estrogen receptor down-regulator (SERD), aromatase inhibitor (AI), or their combination as doublets, used to be the mainstay options as first-line (1L) therapy for most patients...
July 2018: Annals of Translational Medicine
Anna Prange, Beate Bokhof, Philipp Polzer, Joke Tio, Isabel Radke, Oliver Heidinger, Walter Heindel, Stefanie Weigel
PURPOSE:  Assessment of age group-dependent detection rates of invasive breast cancers among participants in mammography screening including the interval, classified into immunohistochemical subtypes indicating the intrinsic tumor aggressiveness. MATERIALS UND METHODS:  The target population comprises women aged 50 - 69 years. All invasive breast cancers diagnosed in one screening (sc) unit during the implementation phase 1/2006 - 12/2010 or identified by the cancer registry during the biennial interval (iv) were categorized based on hormonal-receptor status (HR) and Her2-expression (Her2) into the following subtypes: a) HR+ Her2-, b) HR+ Her2 +, c) HR- Her2 + or d) HR- Her2- (triple-negative); Her2 + and triple-negative types were defined as aggressive...
August 13, 2018: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
Mallory C Campbell, Laura Pontiggia, Ashley Y Russell, Roland Schwarting, Jeanette Camacho, Jean-Francois Jasmin, Isabelle Mercier
Breast cancers (BCas) that lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are referred to as triple negative breast cancers (TNBCs) and have the poorest clinical outcome. Once these aggressive tumors progress to distant organs, the median survival decreases to 12 months. With endocrine therapies being ineffective in this BCa subtype, highly toxic chemo- and radiation therapies are the only options. A better understanding of the functional role(s) of molecular targets contributing to TNBC progression could help in the design and development of new treatments that are more targeted with less toxicity...
July 13, 2018: Oncotarget
Alison Palumbo, Gary Lau, Megan Saraceni
OBJECTIVE: To review the pharmacology, efficacy, and safety of the cyclin-dependent kinase (CDK) inhibitor, abemaciclib, in the treatment of advanced or metastatic breast cancer (MBC). DATA SOURCES: Relevant information was identified through a MEDLINE/PubMed (January 2000 to June 2018) literature search. The new drug application, prescribing information, and abstracts and posters from scientific meetings were also reviewed. STUDY SELECTION/DATA EXTRACTION: The literature search was limited to human studies published in the English language...
August 13, 2018: Annals of Pharmacotherapy
Silvia M Ess, Christian Herrmann, Christine Bouchardy, Isabelle Neyroud, Elisabetta Rapiti, Isabelle Konzelmann, Andrea Bordoni, Laura Ortelli, Sabine Rohrmann, Harald Frick, Mohsen Mousavi, Beat Thürlimann
OBJECTIVE: To study the impact of subtypes and comorbidities on breast cancer (BC) relapse and survival in the heterogeneous patients of the real world. METHODS: We identified patients diagnosed with BC between January 2003 and December 2005 from six population-based Swiss cancer registries. Clinicopathologic data was completed with information on locoregional and distant relapse and date and cause of death for over 10-years. We approximated BC subtypes using grade and the immunohistochemical panel for oestrogen, progesterone and human epidermal growth factor 2 (HER2) receptor status...
July 30, 2018: Breast: Official Journal of the European Society of Mastology
I Witzel, E Laakmann, R Weide, T Neunhöffer, T-J Park-Simon, M Schmidt, P A Fasching, T Hesse, A Polasik, S Mohrmann, F Würschmidt, C Schem, C Bechtner, R Würstlein, T Fehm, V Möbus, N Burchardi, S Loibl, V Müller
BACKGROUND: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited. METHODS: We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions. RESULTS: Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21...
August 9, 2018: European Journal of Cancer
Huina Zhang, Min Han, Kavita R Varma, Beth Z Clark, Rohit Bhargava, David J Dabbs
PURPOSE: Recommendations for standardization of breast biomarkers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) led to the creation of American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines to provide continuous guidance. Included in these recommendations is the "ongoing assay assessment procedures." We report these biomarker metrics as there is a dearth of published information on this topic...
August 8, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Matthias Christgen, Stephan Bartels, Angelina Luft, Sascha Persing, Daniel Henkel, Ulrich Lehmann, Hans Kreipe
In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer. The prevalence of ERBB2/HER2 mutation in bone metastasis of breast cancer and the associated phenotype are not known. In this study, bone metastases from breast cancer patients (n = 231) were analyzed for ERBB2/HER2 mutation. In 7 patients (3%; median age 70 years, range 50-83 years), gain-of-function mutations of ERBB2/HER2 were detected...
August 9, 2018: Virchows Archiv: An International Journal of Pathology
Yoshitaka Fujiki, Yutaka Yamamoto, Aiko Sueta, Mutsuko Yamamoto-Ibusuki, Lisa Goto-Yamaguchi, Mai Tomiguchi, Takashi Takeshita, Hirotaka Iwase
Background: Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (APOBEC3B) is a gene editing enzyme with cytidine deaminase activity and high expression of its mRNA in breast tumors have been shown to be associated with progressive cases and poor prognosis. In this study, we aimed to examine the relationship between the expression of APOBEC3B and the effect of neoadjuvant chemotherapy (NAC) using pretreatment biopsy tissue, and examined whether the expression of APOBEC3B influenced chemotherapy efficacy...
July 17, 2018: Oncotarget
Takuya Osada, Zachary C Hartman, Junping Wei, Gangjun Lei, Amy C Hobeika, William R Gwin, Marcio A Diniz, Neil Spector, Timothy M Clay, Wei Chen, Michael A Morse, H Kim Lyerly
BACKGROUND: Upregulation of human epidermal growth factor receptor 3 (HER3) is a major mechanism of acquired resistance to therapies targeting its heterodimerization partners epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), but also exposes HER3 as a target for immune attack. We generated an adenovirus encoding full length human HER3 (Ad-HER3) to serve as a cancer vaccine. Previously we reported the anti-tumor efficacy and function of the T cell response to this vaccine...
August 9, 2018: Breast Cancer Research: BCR
Joyce O'Shaughnessy, J Thaddeus Beck, Melanie Royce
Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) disease. Advances in treating this type of MBC have focused on improving the efficacy of endocrine therapy by adding agents that target specific molecular pathways of breast cancer cell growth and survival. The combination of the aromatase inhibitor exemestane and the mammalian target of rapamycin inhibitor, everolimus, more than doubled median progression-free survival compared with exemestane alone (7...
July 23, 2018: Cancer Treatment Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"